ROSEMONT PHARMS
PharmaROSEMONT PHARMS is a pharmaceutical company focused on Cardiovascular. Key products include VOSTALLY.
ROSEMONT PHARMS's Key Drugs
ROSEMONT PHARMS's core commercial portfolio centers on ATMEKSI, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
ROSEMONT PHARMS's Recent FDA Approvals
ROSEMONT PHARMS secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
ROSEMONT PHARMS's Therapeutic Areas
ROSEMONT PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ROSEMONT PHARMS's Top Competitors
ROSEMONT PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ROSEMONT PHARMS Pipeline Snapshot
Active clinical trials for ROSEMONT PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ATMEKSI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling